Breast Cancer | Oncology Today with Dr Neil Love: Genomic Assays in Early Breast Cancer

published 1 month ago by Dr Neil Love

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Genomic assays in early-stage breast cancer (0:00) Case: A woman in her early 30s with a family history of breast cancer is diagnosed with hormone receptor (HR)-positive disease and receives a 21-gene assay Recurrence Score® (RS) of 16 (35:08) Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer and a 21-gene RS of 11 receives a recommendation of radiation therapy and an aromatase inhibitor (38:45) Case: A woman in her mid-20s with ER-positive, PR-negative, HER2-negative breast cancer and axillary involvement receives a MammaPrint® high score (40:42) Design and key findings of the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative early breast cancer with 1 to 3 positive lymph nodes and a 21-gene RS of 25 or lower (43:42) Benefit of chemotherapy for premenopausal versus postmenopausal patients enrolled in the RxPONDER trial (47:15) Predictors of late recurrence; use of ctDNA (circulating tumor DNA) as a biomarker of recurrence (51:40) Utility of the RSClin educational tool integrating the 21-gene RS and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit for patients with HR-positive, HER2-negative, node-negative breast cancer (56:59) Impact of the COVID-19 vaccine on screening for breast cancer (1:00:30) Perspective on the use of genomic assays in the neoadjuvant setting (1:02:41) Age-associated benefit from chemotherapy for women with luminal breast cancer in the MINDACT trial (1:06:53) CME information and select publications

more episodes from Research To Practice | Oncology Videos